{"id":1019310,"date":"2026-11-10T07:24:34","date_gmt":"2026-11-10T12:24:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/"},"modified":"2026-11-10T07:24:34","modified_gmt":"2026-11-10T12:24:34","slug":"biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/","title":{"rendered":"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN CARLOS, Calif., Nov.  10, 2026  (GLOBE NEWSWIRE) &#8212; Biomea Fusion, Inc. (\u201cBiomea\u201d) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek<sup>\u00ae<\/sup> 2026. The conference will take place November 14\u201317, 2026, at the Gaylord National Resort &amp; Convention Center in National Harbor, Maryland.<\/p>\n<p>\n        <strong>Presentation Details<\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> First-In-Human Study Results for BMF-650 a Small Molecule Oral GLP-1 Receptor Agonist<br \/><strong>Session:<\/strong> Obesity-Related Complications &amp; Multimorbidity<br \/><strong>Poster Number: <\/strong>Poster 828<br \/><strong>Presenter:<\/strong> Thorsten A. Kirschberg, Ph.D.<br \/><strong>Session Date\/Time:<\/strong> Monday, November 16, 2026, at 2:30 p.m. \u2013 3:30 p.m. ET<\/p>\n<p>After the conference concludes, the poster will be available in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z5bY9jknDsMVHlMtciEHWUa5a7LS8KBJUiaz8jc7orKyKm0cvCYaDljAYqB8UlUNLemFO1GjU0AELAsPjxd81m6yx1pf886ArSL8bFKC-1AbhoESpdEktnArqFjsAX5Zz686aQ0hNH9BuCwKWpQB-g==\" rel=\"nofollow\" target=\"_blank\">Investors &amp; Media<\/a> section of the company\u2019s website.<\/p>\n<p>\n        <strong>About Biomea Fusion\u00a0\u00a0<\/strong><br \/>\n        <br \/>Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world\u2019s population. Biomea\u2019s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity and related conditions. We aim to cure.<\/p>\n<p>Visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WVnGFbJj16OzqY-X0QTDYjy_m1ncO3yhbB9F7BpMP9TFQx8Yh_8YWtfog9GXm01VPpC3DrGrrTvXPVTw4l36KdcSCTuW0oqWJwAF7Rnt1Kw=\" rel=\"nofollow\" target=\"_blank\">www.biomeafusion.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uVwi7nu9CJaeGsPypMJl1zv7jcu06SdgchnU_IsdE2JXkaWlxS3K2AEMDWTTBCdvMfdFGWwK0NbTUdUUDaCMIqBX0NzuZEJVIJ2fEIOwAr4hyt8c2_TE-1-n1gtBkzngmWMKSw9lBXxFO_4bPZ6zhUI4JPEe3o3WUTCiw-F2Nd557yrF06GVGHCcY9ITq1EB65eJweuzsfP3lVBFYrE1IMu2UAjLe57wVpe2gCnh09XadV1xWsr7tMQdwEAS7EErnil-elnIa-9FxZbw9QpSAA==\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MdG6nhHx4_3En0tI_M8n9wUB0eZ9ctAKY7PV0eSXAsNBKPRlnnHlJhVShQSb5LZFG9skw6p1wGzrbg_OuM0mz52bD7zlACZoPXW2gvu1sn2tTGvNSPXH0ZHeaqHQDSNRIhpIvvu5qI5dBjgycgQ6IjjOGxiObMbIAbf8PdxCBOeXYIpcI4-mEC7mow65_T0069BQ3_40FgGUl_1aNdAg1g==\" rel=\"nofollow\" target=\"_blank\"><u>X <\/u><\/a>and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3fAmHq88y8fGPQt1w4kMQxF-1kSD3End7V57IWqz8OWFrqws7A2i-ptyIwtHqHW8KE4HsR07D7UO0XGkX87F9pM-jSwkjAq4vfD9V5S3Yhd5F3j6965516Vr6-rYU68pWFnOmc-KwqcNaCscz_Dh4TNnkrulovLoogySEVK_iWY5_qCDIUQhlUqCA5gPYO8vXsNycU8aPUjeHPmaUfK2_NRNflFSOHMLOvDCs0tVzhJju6zPczSq6fmg3TkFlRJe\" rel=\"nofollow\" target=\"_blank\"><u>Facebook<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact: <\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Meichiel Jennifer Weiss<br \/>Sr. Director of Investor Relations and Corporate Development <br \/>ir@biomeafusion.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmIyODAyN2UtNmI5OC00NDY0LTg3MzYtZGIwYzcyMTUwODYzLTEyMjAxMjUtMjAyNi0xMS0xMC1lbg==\/tiny\/Biomea-Fusion-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Biomea Fusion, Inc. (\u201cBiomea\u201d) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek\u00ae 2026. The conference will take place November 14\u201317, 2026, at the Gaylord National Resort &amp; Convention Center in National Harbor, Maryland. Presentation Details Title: First-In-Human Study Results for BMF-650 a Small Molecule Oral GLP-1 Receptor AgonistSession: Obesity-Related Complications &amp; MultimorbidityPoster Number: Poster 828Presenter: Thorsten A. Kirschberg, Ph.D.Session Date\/Time: Monday, November 16, 2026, at 2:30 p.m. \u2013 3:30 p.m. ET After the conference concludes, the poster will be available in the Investors &amp; Media &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019310","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Biomea Fusion, Inc. (\u201cBiomea\u201d) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek\u00ae 2026. The conference will take place November 14\u201317, 2026, at the Gaylord National Resort &amp; Convention Center in National Harbor, Maryland. Presentation Details Title: First-In-Human Study Results for BMF-650 a Small Molecule Oral GLP-1 Receptor AgonistSession: Obesity-Related Complications &amp; MultimorbidityPoster Number: Poster 828Presenter: Thorsten A. Kirschberg, Ph.D.Session Date\/Time: Monday, November 16, 2026, at 2:30 p.m. \u2013 3:30 p.m. ET After the conference concludes, the poster will be available in the Investors &amp; Media &hellip; Continue reading &quot;Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T12:24:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026\",\"datePublished\":\"2026-11-10T12:24:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/\"},\"wordCount\":238,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/\",\"name\":\"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=\",\"datePublished\":\"2026-11-10T12:24:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/","og_locale":"en_US","og_type":"article","og_title":"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026 - Market Newsdesk","og_description":"SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Biomea Fusion, Inc. (\u201cBiomea\u201d) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek\u00ae 2026. The conference will take place November 14\u201317, 2026, at the Gaylord National Resort &amp; Convention Center in National Harbor, Maryland. Presentation Details Title: First-In-Human Study Results for BMF-650 a Small Molecule Oral GLP-1 Receptor AgonistSession: Obesity-Related Complications &amp; MultimorbidityPoster Number: Poster 828Presenter: Thorsten A. Kirschberg, Ph.D.Session Date\/Time: Monday, November 16, 2026, at 2:30 p.m. \u2013 3:30 p.m. ET After the conference concludes, the poster will be available in the Investors &amp; Media &hellip; Continue reading \"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-10T12:24:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026","datePublished":"2026-11-10T12:24:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/"},"wordCount":238,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/","name":"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=","datePublished":"2026-11-10T12:24:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDA2NSM3OTU2NDAxIzIyMDg1NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek\u00ae 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019310"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019310\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}